Skip to main content

Table 1 Demographics, blood tests results at intensive care unit (ICU) admission and during ICU stay, outcomes and complications of the overall population and according to different subgroups

From: Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units

  Overall
(N = 852)
Enhanced thromboprophylaxis [enoxaparin]
(N = 236, 27.7%)
Enhanced thromboprophylaxis
[other]
(N = 38, 4.5%)
Standard prophylaxis
(N = 435, 51%)
Anticoagulation for indication other than prophylaxis [i.e. PE / DVT on admission]
(N = 143, 16.8%)
Sex, male, n (%) 677 (79.5) 187 (79.2) 31 (81.6) 340 (78.2) 119 (83.2)
Age, years 66 (37–85) 66 (37–85) 65.5 (37–86) 66 (16–87) 67 (27–85)
Comorbidities, n (%)
Hypertension 446 (52.3) 127 (53.8) 16 (42.1) 217 (49.9) 57 (39.9)
Diabetes mellitus 143 (16.8) 37 (15.7) 1 (2.6) 79 (18.2) 26 (18.2)
Renal disease 44 (5.2) 14 (5.9) 0 (0.0) 29 (6.7) 1 (0.7)
Cardiac dysfunction 86 (10.1) 26 (11) 1 (2.6) 41 (9.4) 18 (12.6)
Liver disease 16 (1.9) 2 (0.8) 2 (5.2) 10 (2.3) 2 (1.4)
Obesity (BMI > 30 kg/m2) 235 (27.6) 72 (30.5) 10 (26.3) 111 (25.5) 42 (29.4)
Bloods at ICU admission, median (IQR)
WBC, cells × 109/L 9.0 (1–89) 10.6 (1–46) 9.4 (3–18) 9.0 (2–89) 9.1 (3–45)
D-dimer, ng/mL 1340 (150–136,076) 1610 (93–105,990) 2291 (180–76,400) 1207 (150–129,064) 1484 (85–136,076)
Platelets, cells3/µL 223 (31–734) 218 (255–654) 219 (133–517) 218 (200–734) 234 (70–814)
Fibrinogen, mg/dL 637 (77–1323) 613 (100–1276) 649 (163–999) 635 (40–1196) 626.5 (77–1323)
C-reactive protein, mg/L 102.3 (1–559) 146 (0–559) 162 (3–387) 136.5 (0–393) 138.5 (1–255)
Troponin-I, ng/mL 0.02 (0–6) 0.02 (0–2) 0.03 (0–0) 0.02 (0–21) 0.02 (0–3)
Creatinine, mg/dL 0.93 (0–7) 0.82 (0–7) 1 (1–3) 0.95 (0–7) 0.9 (0–8)
PaO2, mmHg 80 (25–440) 76.5 (27–316) 67.5 (34–189) 85 (25–440) 83 (39–489)
Bloods during ICU stay, median (IQR)
WBC, cells × 109/L
 Lowest 6.1 (0–44) 6.0 (1–24) 6.3 (2–18) 6.1 (1–31) 5.9 (1–44)
 Highest 17.5 (2–132) 17.8 (2–132) 15.3 (2–31) 16.8 (3–68) 19.6 (5–80)
D-dimer, ng/mL
 Highest 4395 (176–222,032) 4706.5 (635–222,032) 6320 (703–798,94) 3637.5 (201–57,588) 5273.5 (201–57,588)
Platelets, cells3/µL
 Lowest 169 (110–510) 174 (30–315) 189 (91–476) 173 (18–510) 146 (11–476)
 Highest 380 (700–981) 397 (175–981) 417 (154–645) 379 (118–953) 366 (70–645)
Troponin-I, ng/mL
 Highest 0.04 (0–10) 0.03 (0–2) 0.03 (0–0) 0.03 (0–10) 0.05 (0–5)
Creatinine, mg/dL
 Highest 1.4 (0.4–14) 1.3 (0–12) 1.2 (1–6) 1.4 (0–9) 1.6 (1–14)
PaO2, mmHg
 Lowest 61 (26–150) 61 (30–107) 60.9 (34–88) 61 (26–150) 62 (33–130)
Thromboembolic complications* n (%)
Arterial embolism 8 (0.9) 6 (2.5) 0 (0.0) 2 (0.5) 0 (0)
DVT 28 (3.2) 11 (4.6) 0 (0.0) 17 (3.9) 0 (0)
Line clotted 21 (2.4) 5 (2.1) 1 (2.6) 15 (3.4) 0 (0)
Pulmonary embolism 57 (6.6) 21 (8.8) 4 (10.5) 32 (7.4) 0 (0)
No/NA 738 (86.6) 193 (82.0) 33 (86.9) 369 (84.8) 0 (0)
Haemorrhagic complications n (%)
Critical haemorrhage 47 (5.5) 12 (5.0) 0 (0.0) 27 (6.2) 8 (5.6)
Non-critical haemorrhage 58 (6.8) 16 (6.9) 2 (5.3) 28 (6.4) 12 (8.4)
No/NA 747 (87.7) 208 (88.1) 36 (94.7) 380 (87.4) 123 (86.0)
  1. IQR, interquartile range; BMI, body mass index; WBC, white blood cells; PaO2,partial pressure of oxygen; AKI, acute kidney injury; RRT, renal replacement therapy; DVT, deep venous thrombosis; PE, pulmonary embolism; NA, not available. * after ICU admission and initiation of anticoagulant regimen